Clinical Trials Logo

Filter by:
NCT ID: NCT06452849 Recruiting - Clinical trials for Major Depressive Disorder

Amygdala and dLPFC MRI-TIS for Depression in Adolescents

Start date: May 27, 2024
Phase: N/A
Study type: Interventional

The study utilizes a non-invasive deep brain stimulation (temporal interference, TI) technique primarily targeting the amygdala to preliminarily explore the clinical efficacy and potential mechanisms of MRI-compatible TI technology in regulating the amygdala in adolescent depressive disorders.

NCT ID: NCT06452550 Recruiting - Radiomics Clinical Trials

Neurophenotype Predicts CD Disease Progression

Start date: May 1, 2021
Phase:
Study type: Observational

The goal of this observational study is aimed to develop a novel multimodal neuroimaging-based model to characterize the neurophenotype of Crohn's Disease patients and assess its ability for predicting disease progression, using multiomics data to interpret the model. Participants will be followed-up of at least six months for patients without disease progression to assess the relationship between neurophenotype and intestinal outcomes.

NCT ID: NCT06452303 Recruiting - Clinical trials for Laboratory and Examination Results During Follow-up

The Patient Cohort for Bariatric Surgery

Start date: February 1, 2024
Phase:
Study type: Observational

This study is based at the National Integrated Traditional Chinese and Western Medicine Medical Center and leverages the centralized strengths of our department, which integrates multiple disciplines (general surgery, endocrinology, nutrition, exercise, and traditional Chinese medicine). It focuses on key scientific issues in the comprehensive management of bariatric surgery throughout the entire treatment cycle. By recording key indicators of patients before and after surgery and using methods such as machine learning to predict postoperative complications, we aim to enhance precision management. Ultimately, we will establish a refined diagnosis and treatment system for metabolic weight loss surgery, promote its application, and thereby raise the standardized management level of weight loss and metabolic disciplines in our hospital and primary care units nationwide. This will improve patient outcomes and reduce the healthcare burden.

NCT ID: NCT06451887 Recruiting - Ischemic Stroke Clinical Trials

Early Identification of Malignant Brain Edema in laRge Artery oCclusive Stroke After Endovascular Therapy (EMBRACE Study)

EMBRACE
Start date: April 1, 2024
Phase:
Study type: Observational [Patient Registry]

To design and validate a predictive model for malignant brain edema after endovascular thrombectomy.

NCT ID: NCT06451848 Recruiting - Clinical trials for Gouty Arthritis (GA)

A Bioequivalence Study of Two Different Dosage Form of Genakumab

Start date: June 29, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate whether Genakumab Injection is bioequivalent to Genakumab for Injection.

NCT ID: NCT06451627 Recruiting - Sleep Disturbance Clinical Trials

Esketamine on Postoperative Sleep Disturbance of Patients Undergoing Spinal Surgery

Start date: June 10, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about the effect of intraoperative esketamine infusion on postoperative sleep disturbance(PSD) of patients undergoing spinal surgery. The main aims to answer are: - To explore the effect of intraoperative infusion of esketamine on the incidence of postoperative sleep disturbance and sleep quality in patients undergoing spinal surgery. - To explore the effect of intraoperative infusion of esketamine on postoperative pain, anxiety and depression ; Participants will be patients undergoing spinal surgery with general anesthesia at Beijing Tiantan Hospital. 0.3mg/kg/h esketamine or saline will be infused during surgery . The incidence of sleep disturbance , sleep quality, pain scores, hospital anxiety and depression scores and perioperative adverse events after surgery will be investigated.

NCT ID: NCT06451393 Recruiting - Gastric Cancer Clinical Trials

Predicting Gastric Cancer Response to Chemo With Multimodal AI Model

Start date: February 1, 2013
Phase:
Study type: Observational

This study aims to develop a multimodal model combining radiomic and pathomic features to predict pathological complete response (pCR) in advanced gastric cancer patients undergoing neoadjuvant chemotherapy (NAC). The researchers intended to collected pre-intervention CT images and pathological slides from patients, extract radiomic and pathomic features, and build a prediction model using machine learning algorithms. The model will be validated using a separate cohort of patients. This research intend to build a radiomic-pathomic model that can outperform models based on either radiomic or pathomic features alone, aiming to improve the prediction of pCR in gastric cancer.

NCT ID: NCT06451211 Recruiting - Gastric Cancer Clinical Trials

Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer

Neo-ICEBOAT
Start date: May 17, 2023
Phase: Phase 2
Study type: Interventional

The aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer. Participants will take the anti-PD-1 inhibitor (Tislelizumab) and platinum-based chemotherapy (oxaliplatin + capecitabine or oxaliplatin + S-1) in a 3-week cycle, followed by a radical operation after 6 cycles.

NCT ID: NCT06451172 Recruiting - Eye Diseases Clinical Trials

Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis

ASOTARI
Start date: October 11, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.

NCT ID: NCT06450145 Recruiting - Tumour Clinical Trials

Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL

APL
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

This study was a single-arm, open study. After the screening period, arsenic-resistant APL patients were treated with interferon α-2b, arsenic and venetoclax. The efficacy (ORR) and safety were evaluated.